Citations (83)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Julie Rask Larsen, Lorena Dima, Christoph U. Correll & Peter Manu. (2018) The pharmacological management of metabolic syndrome. Expert Review of Clinical Pharmacology 11:4, pages 397-410.
Read now
Read now
Xinran Wang, Wei Li, Lijuan Hao, Honglei Xie, Chenzhou Hao, Chunchi Liu, Wenyan Li, Xuqiong Xiong & Dongmei Zhao. (2018) The therapeutic potential of CETP inhibitors: a patent review. Expert Opinion on Therapeutic Patents 28:4, pages 331-340.
Read now
Read now
Hisashi Shinkai. (2012) Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases. Vascular Health and Risk Management 8, pages 323-331.
Read now
Read now
Laia Salvadó, Lucía Serrano-Marco, Emma Barroso, Xavier Palomer & Manuel Vázquez-Carrera. (2012) Targeting PPARβ/δ for the treatment of type 2 diabetes mellitus. Expert Opinion on Therapeutic Targets 16:2, pages 209-223.
Read now
Read now
Kurt Bestehorn, Wenefrieda Smolka, David Pittrow, Helmut Schulte & Gerd Assmann. (2010) Atherogenic dyslipidemia as evidenced by the lipid triad: prevalence and associated risk in statin-treated patients in ambulatory care. Current Medical Research and Opinion 26:12, pages 2833-2839.
Read now
Read now
Fabrizio Montecucco, Alessandra Quercioli, Franco Dallegri, Giorgio Luciano Viviani & François Mach. (2010) New evidence for nicotinic acid treatment to reduce atherosclerosis. Expert Review of Cardiovascular Therapy 8:10, pages 1457-1467.
Read now
Read now
Chris J Packard. (2010) Optimizing lipid-lowering therapy in the prevention of coronary heart disease. Expert Review of Clinical Pharmacology 3:5, pages 649-661.
Read now
Read now
Ekaterini Vourvouhaki & George V Dedoussis. (2008) Cholesterol ester transfer protein: a therapeutic target in atherosclerosis?. Expert Opinion on Therapeutic Targets 12:8, pages 937-948.
Read now
Read now
Vasilios G Athyros, Konstantinos Tziomalos, Dimitri P Mikhailidis, Efstathios D Pagourelias, Anna I Kakafika, Athanasios Skaperdas, Apostolos Hatzitolios & Asterios Karagiannis. (2007) Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. Expert Opinion on Pharmacotherapy 8:14, pages 2267-2277.
Read now
Read now
Irene F Gazi, Vasilis Tsimihodimos, Alexandros D Tselepis, Moses Elisaf & Dimitri P Mikhailidis. (2007) Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opinion on Biological Therapy 7:1, pages 53-72.
Read now
Read now
Articles from other publishers (73)
Shaunak Mangeshkar, Natalia Nazarenko, Dimitrios Varrias, Michail Spanos, Pawel Borkowski, Majd Al Deen Alhuarrat, Weijia Li, Preeti Kishore & Robert T Faillace. (2023) A Case of Type V Hyperlipoproteinemia Resistant to Insulin Treatment. Cureus.
Crossref
Crossref
Natalie C. Ward, Wann Jia Loh & Gerald F. Watts. 2023. Lipoproteins in Diabetes Mellitus. Lipoproteins in Diabetes Mellitus
357
406
.
Maryam Aref, Ariyo Movahedi, Motahar Heidari-Beni & Roya Kelishadi. (2022) Effects of shrimp oil on cardio-metabolic risk factors in children and adolescents. International Journal for Vitamin and Nutrition Research.
Crossref
Crossref
Richu & Ashwani Kumar. (2021)
A Comprehensive Study on Molecular Interactions of
l
-Ascorbic Acid/Nicotinic Acid in Aqueous [BMIm]Br at Varying Temperatures and Compositions: Spectroscopic and Thermodynamic Insights
. Journal of Chemical & Engineering Data 66:10, pages 3859-3880.
Crossref
Crossref
Alan ChaitRobert H. Eckel. (2019) The Chylomicronemia Syndrome Is Most Often Multifactorial. Annals of Internal Medicine 170:9, pages 626.
Crossref
Crossref
Zhixiong Zhong, Jing Liu, Bing Li, Cunren Li, Zhidong Liu, Min Yang, Qifeng Zhang, Wei Zhong & Pingsen Zhao. (2017) Serum lipid profiles in patients with acute myocardial infarction in Hakka population in southern China. Lipids in Health and Disease 16:1.
Crossref
Crossref
Anjeza PashajMengna XiaRégis Moreau. (2015) α-Lipoic acid as a triglyceride-lowering nutraceutical. Canadian Journal of Physiology and Pharmacology 93:12, pages 1029-1041.
Crossref
Crossref
Yong Wei, Baozhen Qi, Juan Xu, Genqing Zhou, Songwen Chen, Ping Ouyang & Shaowen Liu. (2014) Age- and sex-related difference in lipid profiles of patients hospitalized with acute myocardial infarction in East China. Journal of Clinical Lipidology 8:6, pages 562-567.
Crossref
Crossref
Sudhakar S. Dhondge, Prachi N. Dahasahasra, Lalitmohan J. Paliwal & Dinesh W. Deshmukh. (2014) Density and viscosity study of nicotinic acid and nicotinamide in dilute aqueous solutions at and around the temperature of the maximum density of water. The Journal of Chemical Thermodynamics 76, pages 16-23.
Crossref
Crossref
. (2014) Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients. New England Journal of Medicine 371:3, pages 203-212.
Crossref
Crossref
Sandra J. Hamilton & Gerald F. Watts. 2014. Lipoproteins in Diabetes Mellitus. Lipoproteins in Diabetes Mellitus
239
278
.
Vaijinath S. Kamanna, Shobha H. Ganji & Moti L. Kashyap. (2013) Recent advances in niacin and lipid metabolism. Current Opinion in Lipidology 24:3, pages 239-245.
Crossref
Crossref
Y Kishimoto, M Tani & K Kondo. (2013) Pleiotropic preventive effects of dietary polyphenols in cardiovascular diseases. European Journal of Clinical Nutrition 67:5, pages 532-535.
Crossref
Crossref
Indumathi Chennamsetty, Karam M. Kostner, Thierry Claudel, Manjula Vinod, Sasa Frank, Thomas S. Weiss, Michael Trauner & Gerhard M. Kostner. (2012) Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice. Journal of Lipid Research 53:11, pages 2405-2412.
Crossref
Crossref
Kevin C. Maki, Harold E. Bays & Mary R. Dicklin. (2012) Treatment options for the management of hypertriglyceridemia: Strategies based on the best-available evidence. Journal of Clinical Lipidology 6:5, pages 413-426.
Crossref
Crossref
Branko Simic, Matthias Hermann, Sidney G. Shaw, Laurent Bigler, Urs Stalder, Carola Dörries, Christian Besler, Thomas F. Lüscher & Frank Ruschitzka. (2012) Torcetrapib impairs endothelial function in hypertension. European Heart Journal 33:13, pages 1615-1624.
Crossref
Crossref
Maria-Carmen Fernandez, Ana Escribano, Ana I. Mateo, Saravanan Parthasarathy, Eva M. Martin de la Nava, Xiaodong Wang, Sandra L. Cockerham, Thomas P. Beyer, Robert J. Schmidt, Guoqing Cao, Youyan Zhang, Timothy M. Jones, Anthony Borel, Stephanie A. Sweetana, Ellen A. Cannady, Gregory Stephenson, Scott Frank & Nathan B. Mantlo. (2012) Design, synthesis and structure?activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors. Bioorganic & Medicinal Chemistry Letters 22:9, pages 3056-3062.
Crossref
Crossref
Uchechukwu K. Sampson, Sergio Fazio & MacRae F. Linton. (2011) Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. Current Atherosclerosis Reports 14:1, pages 1-10.
Crossref
Crossref
Jieli Chen & Michael Chopp. 2012. Translational Stroke Research. Translational Stroke Research
231
249
.
Geng Zhang, An Pan, Geng Zong, Zhijie Yu, Hongyu Wu, Xiafei Chen, Lixin Tang, Ying Feng, Hong Zhou, Xiaolei Chen, Huaixing Li, Biling Hong, Vasanti S. Malik, Walter C. Willett, Donna Spiegelman, Frank B. Hu & Xu Lin. (2011) Substituting White Rice with Brown Rice for 16 Weeks Does Not Substantially Affect Metabolic Risk Factors in Middle-Aged Chinese Men and Women with Diabetes or a High Risk for Diabetes. The Journal of Nutrition 141:9, pages 1685-1690.
Crossref
Crossref
D. John Betteridge. (2011) Lipid control in patients with diabetes mellitus. Nature Reviews Cardiology 8:5, pages 278-290.
Crossref
Crossref
Michael H. Davidson. (2011) Focusing on High-Density Lipoprotein for Coronary Heart Disease Risk Reduction. Cardiology Clinics 29:1, pages 105-122.
Crossref
Crossref
Alexandros Vakalopoulos, Carsten Schmeck, Michael Thutewohl, Volkhart Li, Hilmar Bischoff, Klemens Lustig, Olaf Weber, Holger Paulsen & Harry Elias. (2011) Chromanol derivatives—A novel class of CETP inhibitors. Bioorganic & Medicinal Chemistry Letters 21:1, pages 488-491.
Crossref
Crossref
Y. Koh, V. Ben-Ezra, K. D. Biggerstaff & D. L. Nichols. (2010) Responses of Blood Lipids and Lipoproteins to Extended-Release Niacin and Exercise in Sedentary Postmenopausal Women. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 65A:9, pages 924-932.
Crossref
Crossref
Anthony S Wierzbicki. (2010) Fibrates: no ACCORD on their use in the treatment of dyslipidaemia. Current Opinion in Lipidology 21:4, pages 352-358.
Crossref
Crossref
Geng Zhang, Vasanti S. Malik, An Pan, Shuba Kumar, Michelle D. Holmes, Donna Spiegelman, Xu Lin & Frank B. Hu. (2010) Substituting Brown Rice for White Rice to Lower Diabetes Risk: A Focus-Group Study in Chinese Adults. Journal of the American Dietetic Association 110:8, pages 1216-1221.
Crossref
Crossref
M. John Chapman, Jan S. Redfern, Mark E. McGovern & Philippe Giral. (2010) Niacin and fibrates in atherogenic dyslipidemia: Pharmacotherapy to reduce cardiovascular risk. Pharmacology & Therapeutics 126:3, pages 314-345.
Crossref
Crossref
Yoshimi Kishimoto, Mariko Tani, Harumi Uto-Kondo, Emi Saita, Maki Iizuka, Hirohito Sone, Kuninobu Yokota & Kazuo Kondo. (2009) Effects of magnesium on postprandial serum lipid responses in healthy human subjects. British Journal of Nutrition 103:4, pages 469-472.
Crossref
Crossref
Sergio Fazio, John R. Guyton, Adam B. Polis, Adeniyi J. Adewale, Joanne E. Tomassini, Nicholas W. Ryan & Andrew M. Tershakovec. (2010) Long-Term Safety and Efficacy of Triple Combination Ezetimibe/Simvastatin Plus Extended-Release Niacin in Patients With Hyperlipidemia. The American Journal of Cardiology 105:4, pages 487-494.
Crossref
Crossref
Anthony S Wierzbicki. (2009) Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia. Current Opinion in Cardiology 24:4, pages 372-379.
Crossref
Crossref
Arshag D Mooradian. (2009) Dyslipidemia in type 2 diabetes mellitus. Nature Reviews Endocrinology 5:3, pages 150-159.
Crossref
Crossref
H. Phatak, C. Wentworth, V. Sazonov & T. Burke. (2009) Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. Atherosclerosis 202:1, pages 225-233.
Crossref
Crossref
Salila Kurra, Tina J. Chahil & Henry N. Ginsberg. 2009. Clinical Lipidology. Clinical Lipidology
443
462
.
Vaijinath S. Kamanna, Shobha H. Ganji & Moti L. Kashyap. (2008) Niacin: An old drug rejuvenated. Current Atherosclerosis Reports 11:1, pages 45-51.
Crossref
Crossref
George Steiner. (2008) Lipid lowering in the patients with prediabetes/metabolic syndrome: what is the evidence?. Current Opinion in Lipidology 19:6, pages 585-591.
Crossref
Crossref
D John Betteridge. (2008) Lipid lowering in diabetes mellitus. Current Opinion in Lipidology 19:6, pages 579-584.
Crossref
Crossref
Eduardo Alegría Ezquerra, José M. Castellano Vázquez & Ana Alegría Barrero. (2008) Obesidad, síndrome metabólico y diabetes: implicaciones cardiovasculares y actuación terapéutica. Revista Española de Cardiología 61:7, pages 752-764.
Crossref
Crossref
Esther M. M. Ooi, P. Hugh R. Barrett, Dick C. Chan & Gerald F. Watts. (2008) Apolipoprotein C-III: understanding an emerging cardiovascular risk factor. Clinical Science 114:10, pages 611-624.
Crossref
Crossref
Ronald B. Goldberg & Terry A. Jacobson. (2008) Effects of Niacin on Glucose Control in Patients With Dyslipidemia. Mayo Clinic Proceedings 83:4, pages 470-478.
Crossref
Crossref
Christie M. Ballantyne, Michael H. Davidson, James M. McKenney, Laurence H. Keller, Daiva R. Bajorunas & Richard H. Karas. (2008) Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. Journal of Clinical Lipidology 2:2, pages 79-90.
Crossref
Crossref
Vaijinath S. Kamanna & Moti L. Kashyap. (2008) Mechanism of Action of Niacin. The American Journal of Cardiology 101:8, pages S20-S26.
Crossref
Crossref
Helene GlassbergDaniel J. Rader. (2008) Management of Lipids in the Prevention of Cardiovascular Events. Annual Review of Medicine 59:1, pages 79-94.
Crossref
Crossref
Jaap Keijer & Evert M van Schothorst. (2008) Adipose tissue failure and mitochondria as a possible target for improvement by bioactive food components. Current Opinion in Lipidology 19:1, pages 4-10.
Crossref
Crossref
Eduardo Alegría Ezquerra, José M. Castellano Vázquez & Ana Alegría Barrero. (2008) Obesity, Metabolic Syndrome, and Diabetes: Cardiovascular Implications and Therapy. Revista Española de Cardiología (English Edition) 61:7, pages 752-764.
Crossref
Crossref
Scott D. Mendelson. 2008. Metabolic Syndrome and Psychiatric Illness. Metabolic Syndrome and Psychiatric Illness
141
186
.
Ronald B. Goldberg MD. 2008. Controversies in Treating Diabetes. Controversies in Treating Diabetes
291
315
.
M. L. Rufail, H. A. Schenkein, T. E. Koertge, A. M. Best, S. E. Barbour, J. G. Tew & R. van Antwerpen. (2007) Atherogenic lipoprotein parameters in patients with aggressive periodontitis. Journal of Periodontal Research 42:6, pages 495-502.
Crossref
Crossref
Vaijinath S. Kamanna & Moti L. Kashyap. (2007) Nicotinic Acid (Niacin) Receptor Agonists: Will They Be Useful Therapeutic Agents?. The American Journal of Cardiology 100:11, pages S53-S61.
Crossref
Crossref
Carol E. O'NeilTheresa A. Nicklas. (2016) State of the Art Reviews: Relationship Between Diet/ Physical Activity and Health. American Journal of Lifestyle Medicine 1:6, pages 457-481.
Crossref
Crossref
J. Shepherd. (2007) Dyslipidaemia in diabetic patients: time for a rethink. Diabetes, Obesity and Metabolism 9:5, pages 609-616.
Crossref
Crossref
Ronald Goldberg. 2007. Comprehensive Management of High Risk Cardiovascular Patients. Comprehensive Management of High Risk Cardiovascular Patients
187
253
.
Eberhard WindlerMark SchöffauerBirgit-Christiane Zyriax. (2016) The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. Diabetes and Vascular Disease Research 4:2, pages 136-142.
Crossref
Crossref
Sandra J Hamilton, Gerard T Chew & Gerald F Watts. (2016) Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. Diabetes and Vascular Disease Research 4:2, pages 89-102.
Crossref
Crossref
Régine L. Sitruk-Ware, Joël Menard, Mandana Rad, Jacobus Burggraaf, Marieke L. de Kam, Barbara A. Tokay, Irving Sivin & Cornelis Kluft. (2007) Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. Contraception 75:6, pages 430-437.
Crossref
Crossref
Consuelo Plata, Caroline R. Sussman, Aleksandra Sind̄ić, Jennifer O. Liang, David B. Mount, Zara M. Josephs, Min-Hwang Chang & Michael F. Romero. (2007) Zebrafish Slc5a12 Encodes an Electroneutral Sodium Monocarboxylate Transporter (SMCTn). Journal of Biological Chemistry 282:16, pages 11996-12009.
Crossref
Crossref
Xiayang Qiu, Anil Mistry, Mark J Ammirati, Boris A Chrunyk, Ronald W Clark, Yang Cong, Jeffrey S Culp, Dennis E Danley, Thomas B Freeman, Kieran F Geoghegan, Matthew C Griffor, Steven J Hawrylik, Cheryl M Hayward, Preston Hensley, Lise R Hoth, George A Karam, Maruja E Lira, David B Lloyd, Katherine M McGrath, Kim J Stutzman-Engwall, Ann K Subashi, Timothy A Subashi, John F Thompson, Ing-Kae Wang, Honglei Zhao & Andrew P Seddon. (2007) Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nature Structural & Molecular Biology 14:2, pages 106-113.
Crossref
Crossref
Daniel J Rader. (2007) Mechanisms of Disease: HDL metabolism as a target for novel therapies. Nature Clinical Practice Cardiovascular Medicine 4:2, pages 102-109.
Crossref
Crossref
Ghazi Hussein, Takako Nakagawa, Hirozo Goto, Yutaka Shimada, Kinzo Matsumoto, Ushio Sankawa & Hiroshi Watanabe. (2007) Astaxanthin ameliorates features of metabolic syndrome in SHR/NDmcr-cp. Life Sciences 80:6, pages 522-529.
Crossref
Crossref
. (2007) Traitement médicamenteux du diabète de type 2recommandation de bonne pratique. Diabetes & Metabolism 33:1, pages S26-S105.
Crossref
Crossref
Christie M. Ballantyne. (2007) Treatment of Dyslipidemia to Reduce Cardiovascular Risk in Patients with Multiple Risk Factors. Clinical Cornerstone 8, pages S6-S13.
Crossref
Crossref
Ian S. Young & Brona V. Loughrey. 2007. Comprehensive Hypertension. Comprehensive Hypertension
1087
1099
.
Isabelle Demonty, Yen-Ming Chan, Dori Pelled & Peter JH Jones. (2006) Fish-oil esters of plant sterols improve the lipid profile of dyslipidemic subjects more than do fish-oil or sunflower oil esters of plant sterols. The American Journal of Clinical Nutrition 84:6, pages 1534-1542.
Crossref
Crossref
Stuart M GrieveJean-Claude AnsquerAnthony C Keech. (2006) Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes. Future Cardiology 2:6, pages 635-646.
Crossref
Crossref
Ronald Goldberg. 2006. Comprehensive Management of High Risk Cardiovascular Patients. Comprehensive Management of High Risk Cardiovascular Patients
187
254
.
Shobha H Ganji, Lin-Hua Zhang, Vaijinath S Kamanna & Moti L Kashyap. (2006) Effect of niacin on lipoproteins and atherosclerosis. Future Lipidology 1:5, pages 549-557.
Crossref
Crossref
Terje R Pedersen, Gerd Assmann, Jean-Pierre Bassand, M John Chapman, Raimund Erbel & Cesare Sirtori. (2016) Reducing residual cardiovascular risk: the relevance of raising high-density lipoprotein cholesterol in patients on cholesterol-lowering treatment. Diabetes and Vascular Disease Research 3:2_suppl, pages S1-S12.
Crossref
Crossref
Isio Schulz. (2006) Tratamento das dislipidemias: como e quando indicar a combina??o de medicamentos hipolipemiantes. Arquivos Brasileiros de Endocrinologia & Metabologia 50:2, pages 344-359.
Crossref
Crossref
Danielle DuffyDaniel J. Rader. (2006) Emerging Therapies Targeting High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport. Circulation 113:8, pages 1140-1150.
Crossref
Crossref
Ambika Babu & Leon Fogelfeld. (2006) Metabolic Syndrome and Prediabetes. Disease-a-Month 52:2-3, pages 55-144.
Crossref
Crossref
Luc F Van GaalFrida Peiffer & Dominique Ballaux. (2016) Reducing cardiovascular risk in patients with type 2 diabetes: the potential contribution of nicotinic acid. The British Journal of Diabetes & Vascular Disease 5:6, pages 344-350.
Crossref
Crossref
Sarah H Wild & Christopher D Byrne. (2016) Review: Treatment of lipids to reduce cardiovascular risk among people with the metabolic syndrome or type 2 diabetes. The British Journal of Diabetes & Vascular Disease 5:6, pages 315-319.
Crossref
Crossref
Zachary T. Bloomgarden. (2005) 2nd International Symposium on Triglycerides and HDL. Diabetes Care 28:10, pages 2577-2584.
Crossref
Crossref
Monika Polak. (2005) Metabolic syndrome and dyslipidaemia. Independent Nurse 2005:4.
Crossref
Crossref